

IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

Please amend claims 9 and 40.

Please cancel claims 34 and 47.

1. – 8. (Canceled)

9. (Currently Amended) A method of delivering a protein to a lymphnode of an individual comprising:

- a) identifying said lymphnode that is to have protein delivered to;
- b) locating a site on said individual's body that is proximal to said lymphnode;
- c) administering to said individual by a route of intramuscular administration ~~selected from the group consisting of: intradermal, subcutaneous, intraperitoneal, and intramuscular~~ at said site, a DNA molecule comprising a nucleotide sequence that encodes said protein, wherein said free DNA molecule is a plasmid and wherein said DNA molecule is operably linked to a secretion signal, a promoter and a polyadenylation signal that are functional in a macrophage cell, wherein said promoter is selected from the group consisting of a M-CSFR promoter, a CD156 promoter, a catalase promoter, a p73 promoter, and an FcγRI promoter, and said polyadenylation signal is selected from the group consisting of: an SV40 polyadenylation signal and a bovine growth hormone polyadenylation signal;

wherein said DNA molecule is taken up by a macrophage cell where said nucleotide sequence is expressed to produce said protein in said macrophage cell, and said macrophage cell drains to said lymphnode, and delivers said protein in said lymphnode.

10. – 14.(Canceled)

15. **(Previously presented)** The method of claim 9 wherein said DNA molecule is administered with a composition which facilitates uptake of said DNA molecule by a cell.

16. **(Previously presented)** The method of claims 9 wherein said DNA molecule is administered with bupivacaine.

17. – 39. **(Canceled)**

40. **(Currently Amended)** A method of delivering a protein to a lymphnode of an individual comprising:

- a) identifying said lymphnode that is to have protein delivered to;
 - b) locating a site on said individual's body that is proximal to said lymphnode;
 - c) administering to said individual at said site that is proximal to said lymphnode by direct injection, a free DNA molecule comprising a nucleotide sequence that encodes said protein, wherein said DNA molecule is a plasmid and wherein said free DNA molecule is operably linked to a secretion signal, a promoter and a polyadenylation signal that are functional in a macrophage cell, wherein said promoter is selected from the group consisting of a M-CSFR promoter, a CD156 promoter, a catalase promoter, a p73 promoter, and an FcγRI promoter;
- wherein said free DNA molecule is taken up by a macrophage cell where said nucleotide sequence is expressed to produce said protein in said macrophage cell, and said macrophage cell drains to said lymphnode, and delivers said protein in said lymphnode.

41. **(Previously presented)** The method of claim 40 wherein said DNA molecule is administered by a route of administration selected from the group consisting of: intradermal, subcutaneous, intraperitoneal, and intramuscular.

42. **(Previously presented)** The method of claim 40 wherein said polyadenylation signal is selected from the group consisting of: an SV40 polyadenylation signal and a bovine growth hormone polyadenylation signal.
43. **(Previously presented)** The method of claim 40 wherein said DNA molecule is administered with a composition which facilitates uptake of said DNA molecule by a cell.
44. **(Previously presented)** The method of claim 40 wherein said DNA molecule is administered with bupivacaine.
45. **(Previously presented)** The method of claim 40 wherein said DNA molecule is administered by intramuscular administration.
46. **(Previously presented)** The method of claims 45 wherein said DNA molecule is administered with bupivacaine.
47. **(Canceled)**
48. **(Previously presented)** The method of claim 44 wherein said DNA molecule is administered by intramuscular administration.